首页 > 最新文献

Radiation oncology journal最新文献

英文 中文
Pulsed low-dose rate radiotherapy for recurrent bone sarcomas: case reports and brief review 针对复发性骨肉瘤的脉冲低剂量放射治疗:病例报告和简要回顾
Pub Date : 2024-02-13 DOI: 10.3857/roj.2023.00815
Ru Xin Wong, Zubin Master, Eric Pang, Valerie Yang, W. S. Looi
{"title":"Pulsed low-dose rate radiotherapy for recurrent bone sarcomas: case reports and brief review","authors":"Ru Xin Wong, Zubin Master, Eric Pang, Valerie Yang, W. S. Looi","doi":"10.3857/roj.2023.00815","DOIUrl":"https://doi.org/10.3857/roj.2023.00815","url":null,"abstract":"","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"67 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139841032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison between 1-week and 2-week palliative radiotherapy courses for superior vena cava syndrome. 上腔静脉综合征1周和2周姑息性放疗方案的比较。
Pub Date : 2023-09-01 Epub Date: 2023-09-25 DOI: 10.3857/roj.2023.00626
Jongmoo Park, Jeong Eun Lee

Purpose: The aim of this study was to evaluate the effectiveness of palliative radiation therapy (RT) for superior vena cava (SVC) syndrome from lung cancer and to compare the 2-week and 1-week schedules.

Materials and methods: A retrospective study was conducted on lung cancer patients with palliative RT for SVC syndrome. Patients received 30 Gy in 10 fractions (2-week group) or 20 Gy in 5 fractions (1-week group) between July 2012 and June 2022. Treatment outcomes were evaluated at 1 to 2 months after RT. The tumor response and recanalization were evaluated based on the computed tomography (CT).

Results: Of the 39 patients, 24 received a 2-week course RT and 15 received a 1-week course of RT. The most common SVC-associated symptoms were edema (51.3%) and dyspnea (43.6%). There were no significant differences in performance status, histology, and grade of SVC. Symptom relief in symptomatic patients was comparable (85.7% in the 2-week group vs. 91.6% in the 1-week group; p = 0.581). There were no significant differences between the 2-week and 1-week groups in recanalization rates (62.5% vs. 60.0%; p = 0.876), tumor responses (75% vs. 60.0%; p = 0.876), and 6-month overall survival rates (29.2% vs. 36.4%; p = 0.726). In each of the two groups, one patient was consulted for re-irradiation. The median survival were 3.7 months for the 2-week group and 4.4 months for the 1-week group.

Conclusion: In patients with SVC syndrome, the palliative effect of a 1-week course was equivalent to that of a 2-week course. Given the poor prognosis, a 1-week course may be an option.

目的:本研究旨在评估姑息性放射治疗(RT)治疗癌症上腔静脉(SVC)综合征的有效性,并比较2周和1周的治疗方案。材料与方法:对癌症患者进行SVC综合征姑息性RT的回顾性研究。在2012年7月至2022年6月期间,患者接受了10次30 Gy(2周组)或5次20 Gy(1周组)。在放疗后1至2个月评估治疗结果。根据计算机断层扫描(CT)评估肿瘤反应和再通情况。结果:39名患者中,24名接受了2周疗程的放疗,15名接受了1周疗程的RT。最常见的SVC相关症状是水肿(51.3%)和呼吸困难(43.6%),SVC的组织学和分级。症状患者的症状缓解具有可比性(2周组为85.7%,1周组为91.6%;p=0.581)。2周组和1周组在再通率(62.5%,60.0%;p=0.876)、肿瘤反应(75%,60.0%)和6个月总生存率(29.2%,36.4%;p=0.726)方面没有显著差异,咨询了一名患者进行再次放射治疗。2周组的中位生存期为3.7个月,1周组为4.4个月。结论:对于SVC综合征患者,1周疗程的姑息效果相当于2周疗程。鉴于预后不佳,1周疗程可能是一种选择。
{"title":"Comparison between 1-week and 2-week palliative radiotherapy courses for superior vena cava syndrome.","authors":"Jongmoo Park,&nbsp;Jeong Eun Lee","doi":"10.3857/roj.2023.00626","DOIUrl":"10.3857/roj.2023.00626","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to evaluate the effectiveness of palliative radiation therapy (RT) for superior vena cava (SVC) syndrome from lung cancer and to compare the 2-week and 1-week schedules.</p><p><strong>Materials and methods: </strong>A retrospective study was conducted on lung cancer patients with palliative RT for SVC syndrome. Patients received 30 Gy in 10 fractions (2-week group) or 20 Gy in 5 fractions (1-week group) between July 2012 and June 2022. Treatment outcomes were evaluated at 1 to 2 months after RT. The tumor response and recanalization were evaluated based on the computed tomography (CT).</p><p><strong>Results: </strong>Of the 39 patients, 24 received a 2-week course RT and 15 received a 1-week course of RT. The most common SVC-associated symptoms were edema (51.3%) and dyspnea (43.6%). There were no significant differences in performance status, histology, and grade of SVC. Symptom relief in symptomatic patients was comparable (85.7% in the 2-week group vs. 91.6% in the 1-week group; p = 0.581). There were no significant differences between the 2-week and 1-week groups in recanalization rates (62.5% vs. 60.0%; p = 0.876), tumor responses (75% vs. 60.0%; p = 0.876), and 6-month overall survival rates (29.2% vs. 36.4%; p = 0.726). In each of the two groups, one patient was consulted for re-irradiation. The median survival were 3.7 months for the 2-week group and 4.4 months for the 1-week group.</p><p><strong>Conclusion: </strong>In patients with SVC syndrome, the palliative effect of a 1-week course was equivalent to that of a 2-week course. Given the poor prognosis, a 1-week course may be an option.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"178-185"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cf/2d/roj-2023-00626.PMC10556839.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41176047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical outcomes of radical radiotherapy for pulmonary sarcomatoid carcinoma. 肺肉瘤样癌根治性放疗的临床疗效。
Pub Date : 2023-09-01 Epub Date: 2023-09-14 DOI: 10.3857/roj.2023.00437
Choong-Won Lee, Byoung Hyuck Kim, Hak Jae Kim

Purpose: Pulmonary sarcomatoid carcinoma (PSC) is recognized for its aggressiveness and poor prognosis. The role of radical radiotherapy in PSC remains uncertain due to its scarcity and limited data. In the absence of an effective systemic agent, this study aims to explore the possibility of cure and to investigate potential prognostic factors and treatment outcomes.

Materials and methods: From January 2005 to December 2021, 149 PSC patients were identified. Among 62 patients who received radiotherapy for lung lesions, 25 who underwent palliative radiotherapy and 16 who underwent surgery were excluded.

Results: The median patient age was 71 years. The majority were male, and 17 patients (81.0%) were diagnosed at an advanced stage. After radical radiotherapy, distant metastasis (47.6%) was the most common site of failure, while the local recurrence rate was quite low (9.5%). Eventually, five patients (26.3%) demonstrated either a partial response or complete remission, including three complete remissions with durable responses. The median progression-free survival (PFS) and overall survival were 4.6 months and 7.9 months, respectively. Univariate and multivariate analyses revealed that a tumor size >5 cm was associated with a worse prognosis (p = 0.045), while a radiation dose >58 GyEQD2 was significantly associated with better PFS (p = 0.038).

Conclusion: This study demonstrates clinical outcomes after radical radiotherapy in managing PSC, suggesting tumor size and radiation dose could be a predictor of a systemic response. Given the known bad prognosis but complete remission could be achieved in certain subgroups, future research should explore the potential strategies using radical radiotherapy for this challenging patient population.

目的:肺肉瘤样癌(PSC)因其侵袭性和预后差而被公认。由于其稀缺性和数据有限,根治性放疗在PSC中的作用仍不确定。在缺乏有效的全身药物的情况下,本研究旨在探索治愈的可能性,并研究潜在的预后因素和治疗结果。材料和方法:2005年1月至2021年12月,共鉴定出149例PSC患者。在62名接受肺部病变放射治疗的患者中,25名接受姑息性放射治疗,16名接受手术的患者被排除在外。结果:患者的中位年龄为71岁。大多数是男性,17名患者(81.0%)被诊断为晚期。根治性放疗后,远处转移(47.6%)是最常见的失败部位,而局部复发率很低(9.5%)。最终,5名患者(26.3%)表现出部分缓解或完全缓解,其中3名患者表现出持久缓解。中位无进展生存期(PFS)和总生存期分别为4.6个月和7.9个月。单变量和多变量分析显示,肿瘤大小>5cm与预后较差相关(p=0.045),而辐射剂量>58GyEQD2与PFS较好显著相关(p=0.038)。考虑到已知的不良预后,但在某些亚组中可以实现完全缓解,未来的研究应该探索对这一具有挑战性的患者群体使用根治性放疗的潜在策略。
{"title":"Clinical outcomes of radical radiotherapy for pulmonary sarcomatoid carcinoma.","authors":"Choong-Won Lee,&nbsp;Byoung Hyuck Kim,&nbsp;Hak Jae Kim","doi":"10.3857/roj.2023.00437","DOIUrl":"10.3857/roj.2023.00437","url":null,"abstract":"<p><strong>Purpose: </strong>Pulmonary sarcomatoid carcinoma (PSC) is recognized for its aggressiveness and poor prognosis. The role of radical radiotherapy in PSC remains uncertain due to its scarcity and limited data. In the absence of an effective systemic agent, this study aims to explore the possibility of cure and to investigate potential prognostic factors and treatment outcomes.</p><p><strong>Materials and methods: </strong>From January 2005 to December 2021, 149 PSC patients were identified. Among 62 patients who received radiotherapy for lung lesions, 25 who underwent palliative radiotherapy and 16 who underwent surgery were excluded.</p><p><strong>Results: </strong>The median patient age was 71 years. The majority were male, and 17 patients (81.0%) were diagnosed at an advanced stage. After radical radiotherapy, distant metastasis (47.6%) was the most common site of failure, while the local recurrence rate was quite low (9.5%). Eventually, five patients (26.3%) demonstrated either a partial response or complete remission, including three complete remissions with durable responses. The median progression-free survival (PFS) and overall survival were 4.6 months and 7.9 months, respectively. Univariate and multivariate analyses revealed that a tumor size >5 cm was associated with a worse prognosis (p = 0.045), while a radiation dose >58 GyEQD2 was significantly associated with better PFS (p = 0.038).</p><p><strong>Conclusion: </strong>This study demonstrates clinical outcomes after radical radiotherapy in managing PSC, suggesting tumor size and radiation dose could be a predictor of a systemic response. Given the known bad prognosis but complete remission could be achieved in certain subgroups, future research should explore the potential strategies using radical radiotherapy for this challenging patient population.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"163-171"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/bc/roj-2023-00437.PMC10556836.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41161744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feasibility of artificial intelligence-driven interfractional monitoring of organ changes by mega-voltage computed tomography in intensity-modulated radiotherapy of prostate cancer. 人工智能驱动超高压计算机断层扫描在癌症前列腺调强放疗中器官变化的跨部门监测的可行性。
Pub Date : 2023-09-01 Epub Date: 2023-09-25 DOI: 10.3857/roj.2023.00444
Yohan Lee, Hyun Joon Choi, Hyemi Kim, Sunghyun Kim, Mi Sun Kim, Hyejung Cha, Young Ju Eum, Hyosung Cho, Jeong Eun Park, Sei Hwan You

Purpose: High-dose radiotherapy (RT) for localized prostate cancer requires careful consideration of target position changes and adjacent organs-at-risk (OARs), such as the rectum and bladder. Therefore, daily monitoring of target position and OAR changes is crucial in minimizing interfractional dosimetric uncertainties. For efficient monitoring of the internal condition of patients, we assessed the feasibility of an auto-segmentation of OARs on the daily acquired images, such as megavoltage computed tomography (MVCT), via a commercial artificial intelligence (AI)-based solution in this study.

Materials and methods: We collected MVCT images weekly during the entire course of RT for 100 prostate cancer patients treated with the helical TomoTherapy system. Based on the manually contoured body outline, the bladder including prostate area, and rectal balloon regions for the 100 MVCT images, we trained the commercially available fully convolutional (FC)-DenseNet model and tested its auto-contouring performance.

Results: Based on the optimally determined hyperparameters, the FC-DenseNet model successfully auto-contoured all regions of interest showing high dice similarity coefficient (DSC) over 0.8 and a small mean surface distance (MSD) within 1.43 mm in reference to the manually contoured data. With this well-trained AI model, we have efficiently monitored the patient's internal condition through six MVCT scans, analyzing DSC, MSD, centroid, and volume differences.

Conclusion: We have verified the feasibility of utilizing a commercial AI-based model for auto-segmentation with low-quality daily MVCT images. In the future, we will establish a fast and accurate auto-segmentation and internal organ monitoring system for efficiently determining the time for adaptive replanning.

目的:局部前列腺癌症的高剂量放射治疗(RT)需要仔细考虑靶位变化和邻近的危险器官(OAR),如直肠和膀胱。因此,对目标位置和OAR变化的日常监测对于最大限度地减少交叉剂量测定的不确定性至关重要。为了有效监测患者的内部状况,我们在本研究中通过基于商业人工智能(AI)的解决方案,评估了在日常采集的图像上自动分割OAR的可行性,如兆伏计算机断层扫描(MVCT)。材料和方法:我们每周收集100例使用螺旋TomoTherapy系统治疗的癌症患者在RT的整个过程中的MVCT图像。基于100 MVCT图像的手动轮廓身体轮廓、包括前列腺区域的膀胱和直肠球囊区域,我们训练了商用的全卷积(FC)-DenseNet模型,并测试了其自动轮廓绘制性能。结果:基于最佳确定的超参数,FC DenseNet模型成功地自动绘制了所有感兴趣区域的轮廓,显示出超过0.8的高骰子相似系数(DSC)和1.43mm以内的小平均表面距离(MSD)。有了这个训练有素的AI模型,我们通过六次MVCT扫描,分析DSC、MSD、质心和体积差异,有效地监测了患者的内部状况。结论:我们已经验证了利用商业人工智能模型对低质量的日常MVCT图像进行自动分割的可行性。未来,我们将建立一个快速准确的自动分割和内部器官监测系统,以有效地确定自适应重新规划的时间。
{"title":"Feasibility of artificial intelligence-driven interfractional monitoring of organ changes by mega-voltage computed tomography in intensity-modulated radiotherapy of prostate cancer.","authors":"Yohan Lee,&nbsp;Hyun Joon Choi,&nbsp;Hyemi Kim,&nbsp;Sunghyun Kim,&nbsp;Mi Sun Kim,&nbsp;Hyejung Cha,&nbsp;Young Ju Eum,&nbsp;Hyosung Cho,&nbsp;Jeong Eun Park,&nbsp;Sei Hwan You","doi":"10.3857/roj.2023.00444","DOIUrl":"https://doi.org/10.3857/roj.2023.00444","url":null,"abstract":"<p><strong>Purpose: </strong>High-dose radiotherapy (RT) for localized prostate cancer requires careful consideration of target position changes and adjacent organs-at-risk (OARs), such as the rectum and bladder. Therefore, daily monitoring of target position and OAR changes is crucial in minimizing interfractional dosimetric uncertainties. For efficient monitoring of the internal condition of patients, we assessed the feasibility of an auto-segmentation of OARs on the daily acquired images, such as megavoltage computed tomography (MVCT), via a commercial artificial intelligence (AI)-based solution in this study.</p><p><strong>Materials and methods: </strong>We collected MVCT images weekly during the entire course of RT for 100 prostate cancer patients treated with the helical TomoTherapy system. Based on the manually contoured body outline, the bladder including prostate area, and rectal balloon regions for the 100 MVCT images, we trained the commercially available fully convolutional (FC)-DenseNet model and tested its auto-contouring performance.</p><p><strong>Results: </strong>Based on the optimally determined hyperparameters, the FC-DenseNet model successfully auto-contoured all regions of interest showing high dice similarity coefficient (DSC) over 0.8 and a small mean surface distance (MSD) within 1.43 mm in reference to the manually contoured data. With this well-trained AI model, we have efficiently monitored the patient's internal condition through six MVCT scans, analyzing DSC, MSD, centroid, and volume differences.</p><p><strong>Conclusion: </strong>We have verified the feasibility of utilizing a commercial AI-based model for auto-segmentation with low-quality daily MVCT images. In the future, we will establish a fast and accurate auto-segmentation and internal organ monitoring system for efficiently determining the time for adaptive replanning.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"186-198"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/10/5e/roj-2023-00444.PMC10556843.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41161778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Has the growing evidence of radiotherapy for hepatocellular carcinoma increased the use of radiotherapy in elderly patients? 肝细胞癌放射治疗的证据越来越多,是否增加了老年患者放射治疗的使用?
Pub Date : 2023-09-01 Epub Date: 2023-09-12 DOI: 10.3857/roj.2023.00710
Tae Hyun Kim
Primary liver cancer, mostly hepatocellular carcinoma (HCC), is the sixth most common cancer and the third leading cause of cancer-related deaths worldwide [1]. HCC develops mostly in patients with chronic liver disease, such as cirrhosis from hepatitis B and C virus infection, alcoholic abuse
{"title":"Has the growing evidence of radiotherapy for hepatocellular carcinoma increased the use of radiotherapy in elderly patients?","authors":"Tae Hyun Kim","doi":"10.3857/roj.2023.00710","DOIUrl":"https://doi.org/10.3857/roj.2023.00710","url":null,"abstract":"Primary liver cancer, mostly hepatocellular carcinoma (HCC), is the sixth most common cancer and the third leading cause of cancer-related deaths worldwide [1]. HCC develops mostly in patients with chronic liver disease, such as cirrhosis from hepatitis B and C virus infection, alcoholic abuse","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"141-143"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/75/9f/roj-2023-00710.PMC10556838.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41171430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bleeding metastasis of renal cell cancer to anal canal treated with radiation. 放射治疗肾细胞癌症肛门管出血性转移。
Pub Date : 2023-09-01 Epub Date: 2023-09-18 DOI: 10.3857/roj.2023.00465
Cemal Ulusoy, Sila Guclu Mete, Andrej Nikolovski

Renal cell cancer (RCC) has the ability to metastasize to various organs, including the anal canal which is reported to be the rarest location. An 88-year-old male patient who had previously been treated for right RCC subsequently developed distant metastases to the prostate, lungs, and small bowel. Four years following nephrectomy, the patient presented with a bleeding anal mass which was excised and has been proven to be an anal canal metastasis of RCC. Eight months post excision, regrowth occurred. The patient underwent stereotactic ablative body radiotherapy resulting in satisfactory regression during the 2-month follow-up period, without episodes of bleeding. The treatment options for metastatic post-nephrectomy disease should be considered with a multidisciplinary approach in order to achieve satisfactory symptom relief.

肾细胞癌症(RCC)具有转移到各种器官的能力,包括据报道最罕见的肛门管。一名88岁男性患者先前接受过右肾细胞癌治疗,随后出现前列腺、肺部和小肠的远处转移。肾切除术后四年,患者出现肛门出血肿块,该肿块被切除,已被证明是RCC的肛管转移。切除术后8个月,出现再生。患者接受了立体定向消融身体放射治疗,在2个月的随访期内恢复良好,没有出血。转移性肾切除术后疾病的治疗方案应考虑多学科的方法,以达到令人满意的症状缓解。
{"title":"Bleeding metastasis of renal cell cancer to anal canal treated with radiation.","authors":"Cemal Ulusoy,&nbsp;Sila Guclu Mete,&nbsp;Andrej Nikolovski","doi":"10.3857/roj.2023.00465","DOIUrl":"10.3857/roj.2023.00465","url":null,"abstract":"<p><p>Renal cell cancer (RCC) has the ability to metastasize to various organs, including the anal canal which is reported to be the rarest location. An 88-year-old male patient who had previously been treated for right RCC subsequently developed distant metastases to the prostate, lungs, and small bowel. Four years following nephrectomy, the patient presented with a bleeding anal mass which was excised and has been proven to be an anal canal metastasis of RCC. Eight months post excision, regrowth occurred. The patient underwent stereotactic ablative body radiotherapy resulting in satisfactory regression during the 2-month follow-up period, without episodes of bleeding. The treatment options for metastatic post-nephrectomy disease should be considered with a multidisciplinary approach in order to achieve satisfactory symptom relief.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"217-221"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/61/6c/roj-2023-00465.PMC10556841.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41143833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Developing prompts from large language model for extracting clinical information from pathology and ultrasound reports in breast cancer. 从大型语言模型中开发提示,用于从癌症的病理学和超声报告中提取临床信息。
Pub Date : 2023-09-01 Epub Date: 2023-09-21 DOI: 10.3857/roj.2023.00633
Hyeon Seok Choi, Jun Yeong Song, Kyung Hwan Shin, Ji Hyun Chang, Bum-Sup Jang

Purpose: We aimed to evaluate the time and cost of developing prompts using large language model (LLM), tailored to extract clinical factors in breast cancer patients and their accuracy.

Materials and methods: We collected data from reports of surgical pathology and ultrasound from breast cancer patients who underwent radiotherapy from 2020 to 2022. We extracted the information using the Generative Pre-trained Transformer (GPT) for Sheets and Docs extension plugin and termed this the "LLM" method. The time and cost of developing the prompts with LLM methods were assessed and compared with those spent on collecting information with "full manual" and "LLM-assisted manual" methods. To assess accuracy, 340 patients were randomly selected, and the extracted information by LLM method were compared with those collected by "full manual" method.

Results: Data from 2,931 patients were collected. We developed 12 prompts for Extract function and 12 for Format function to extract and standardize the information. The overall accuracy was 87.7%. For lymphovascular invasion, it was 98.2%. Developing and processing the prompts took 3.5 hours and 15 minutes, respectively. Utilizing the ChatGPT application programming interface cost US $65.8 and when factoring in the estimated wage, the total cost was US $95.4. In an estimated comparison, "LLM-assisted manual" and "LLM" methods were time- and cost-efficient compared to the "full manual" method.

Conclusion: Developing and facilitating prompts for LLM to derive clinical factors was efficient to extract crucial information from huge medical records. This study demonstrated the potential of the application of natural language processing using LLM model in breast cancer patients. Prompts from the current study can be re-used for other research to collect clinical information.

目的:我们旨在评估使用大型语言模型(LLM)开发提示的时间和成本,该模型专门用于提取癌症患者的临床因素及其准确性。材料和方法:我们收集了2020年至2022年接受放疗的癌症患者的手术病理和超声报告数据。我们使用Generative Pre-trained Transformer(GPT)for Sheets and Docs扩展插件提取信息,并将其称为“LLM”方法。评估了使用LLM方法开发提示的时间和成本,并将其与使用“完整手册”和“LLM辅助手册”方法收集信息所花费的时间和费用进行了比较。为了评估准确性,随机选择340名患者,并将LLM方法提取的信息与“全手工”方法收集的信息进行比较。结果:收集了2931例患者的数据。我们为提取功能开发了12个提示,为格式化功能开发了12中的提示,以提取和标准化信息。总体准确率为87.7%。对于淋巴血管侵犯,准确率为98.2%。开发和处理提示分别需要3.5小时和15分钟。使用ChatGPT应用程序编程接口的成本为65.8美元,考虑到估计工资,总成本为95.4美元。在估计的比较中,与“全手动”方法相比,“LLM辅助手动”和“LLM”方法在时间和成本上都是高效的。结论:开发和促进LLM获取临床因素的提示是从大量病历中提取关键信息的有效方法。这项研究证明了使用LLM模型的自然语言处理在癌症患者中的应用潜力。当前研究的提示可以重复用于其他研究,以收集临床信息。
{"title":"Developing prompts from large language model for extracting clinical information from pathology and ultrasound reports in breast cancer.","authors":"Hyeon Seok Choi,&nbsp;Jun Yeong Song,&nbsp;Kyung Hwan Shin,&nbsp;Ji Hyun Chang,&nbsp;Bum-Sup Jang","doi":"10.3857/roj.2023.00633","DOIUrl":"10.3857/roj.2023.00633","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to evaluate the time and cost of developing prompts using large language model (LLM), tailored to extract clinical factors in breast cancer patients and their accuracy.</p><p><strong>Materials and methods: </strong>We collected data from reports of surgical pathology and ultrasound from breast cancer patients who underwent radiotherapy from 2020 to 2022. We extracted the information using the Generative Pre-trained Transformer (GPT) for Sheets and Docs extension plugin and termed this the \"LLM\" method. The time and cost of developing the prompts with LLM methods were assessed and compared with those spent on collecting information with \"full manual\" and \"LLM-assisted manual\" methods. To assess accuracy, 340 patients were randomly selected, and the extracted information by LLM method were compared with those collected by \"full manual\" method.</p><p><strong>Results: </strong>Data from 2,931 patients were collected. We developed 12 prompts for Extract function and 12 for Format function to extract and standardize the information. The overall accuracy was 87.7%. For lymphovascular invasion, it was 98.2%. Developing and processing the prompts took 3.5 hours and 15 minutes, respectively. Utilizing the ChatGPT application programming interface cost US $65.8 and when factoring in the estimated wage, the total cost was US $95.4. In an estimated comparison, \"LLM-assisted manual\" and \"LLM\" methods were time- and cost-efficient compared to the \"full manual\" method.</p><p><strong>Conclusion: </strong>Developing and facilitating prompts for LLM to derive clinical factors was efficient to extract crucial information from huge medical records. This study demonstrated the potential of the application of natural language processing using LLM model in breast cancer patients. Prompts from the current study can be re-used for other research to collect clinical information.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"209-216"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7d/b6/roj-2023-00633.PMC10556835.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41159138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Comparison of sequential versus concurrent chemoradiation regimens in non-metastatic muscle-invasive bladder cancer. 非消化性肌肉浸润性膀胱癌症的连续化疗方案与同期化疗方案的比较。
Pub Date : 2023-09-01 Epub Date: 2023-09-21 DOI: 10.3857/roj.2023.00262
Heidi M Vieira, David P Kasper, Runqiu Wang, Lynette M Smith, Charles A Enke, Raymond C Bergan, Benjamin A Teply, Michael J Baine

Purpose: The treatment approach for non-metastatic bladder cancer is guided by an invasion of the muscular layer of the bladder wall. Radical cystectomy is the recommended treatment for muscle-invasive disease. However, it has considerable morbidity and mortality and is not suited for many patients. Trimodality therapy consisting of chemoradiation after transurethral resection of bladder tumor offers a definitive approach with bladder-sparing potential. However, there is a lack of research defining the optimal combination of chemotherapy and radiation in this setting.

Materials and methods: We extracted patient data from the National Cancer Database to compare survival outcomes and demographic factors in 2,227 non-metastatic bladder cancer patients who were treated with chemotherapy sequential to or concurrently with radiation. Sequential treatment was defined as chemotherapy beginning >14 days before radiation, and concurrent was defined as beginning within 14 days of the first radiation.

Results: The sequential treatment group patients were younger (mean age, 74 vs. 78 years; p < 0.001) with more advanced disease. We found no difference in overall survival between patients who received chemotherapy sequential to radiation and those who received concurrent chemoradiation only (p = 0.533).

Conclusion: Our data are concordant with a previous prospective study, and support that chemotherapy prior to radiation does not decrease survival outcomes relative to patients receiving only concurrent chemoradiation. Given that the sequential group had an overall higher stage but no difference in survival, downstaging chemotherapy prior to radiation may be helpful in these patients. Further studies including a larger, multi-institutional clinical trial are indicated to support clinical decision-making.

目的:以侵犯膀胱壁肌肉层为指导,对非浸润性膀胱癌症进行治疗。根治性膀胱切除术是治疗肌肉侵袭性疾病的推荐方法。然而,它具有相当大的发病率和死亡率,不适合许多患者。经尿道膀胱肿瘤切除术后放化疗组成的三联疗法提供了一种具有保留膀胱潜力的明确方法。然而,在这种情况下,缺乏确定化疗和放疗最佳组合的研究。材料和方法:我们从国家癌症数据库中提取患者数据,以比较2227名非味觉癌症患者的生存结果和人口统计学因素,这些患者在放疗后或放疗后接受化疗。顺序治疗被定义为在放疗前>14天开始化疗,同时治疗被定义为由第一次放疗后14天内开始化疗。结果:序贯治疗组患者年龄较小(平均年龄74岁vs.78岁;p<0.001),病情较晚期。我们发现,在放疗后接受化疗的患者和仅同时接受放化疗的患者之间,总生存率没有差异(p=0.533)。结论:我们的数据与之前的前瞻性研究一致,并支持放疗前化疗不会降低仅同时接受化疗放放疗的患者的生存率。考虑到序贯组的总体分期较高,但存活率没有差异,在放疗前降低化疗分期可能对这些患者有帮助。进一步的研究,包括更大规模的多机构临床试验,表明可以支持临床决策。
{"title":"Comparison of sequential versus concurrent chemoradiation regimens in non-metastatic muscle-invasive bladder cancer.","authors":"Heidi M Vieira,&nbsp;David P Kasper,&nbsp;Runqiu Wang,&nbsp;Lynette M Smith,&nbsp;Charles A Enke,&nbsp;Raymond C Bergan,&nbsp;Benjamin A Teply,&nbsp;Michael J Baine","doi":"10.3857/roj.2023.00262","DOIUrl":"10.3857/roj.2023.00262","url":null,"abstract":"<p><strong>Purpose: </strong>The treatment approach for non-metastatic bladder cancer is guided by an invasion of the muscular layer of the bladder wall. Radical cystectomy is the recommended treatment for muscle-invasive disease. However, it has considerable morbidity and mortality and is not suited for many patients. Trimodality therapy consisting of chemoradiation after transurethral resection of bladder tumor offers a definitive approach with bladder-sparing potential. However, there is a lack of research defining the optimal combination of chemotherapy and radiation in this setting.</p><p><strong>Materials and methods: </strong>We extracted patient data from the National Cancer Database to compare survival outcomes and demographic factors in 2,227 non-metastatic bladder cancer patients who were treated with chemotherapy sequential to or concurrently with radiation. Sequential treatment was defined as chemotherapy beginning >14 days before radiation, and concurrent was defined as beginning within 14 days of the first radiation.</p><p><strong>Results: </strong>The sequential treatment group patients were younger (mean age, 74 vs. 78 years; p < 0.001) with more advanced disease. We found no difference in overall survival between patients who received chemotherapy sequential to radiation and those who received concurrent chemoradiation only (p = 0.533).</p><p><strong>Conclusion: </strong>Our data are concordant with a previous prospective study, and support that chemotherapy prior to radiation does not decrease survival outcomes relative to patients receiving only concurrent chemoradiation. Given that the sequential group had an overall higher stage but no difference in survival, downstaging chemotherapy prior to radiation may be helpful in these patients. Further studies including a larger, multi-institutional clinical trial are indicated to support clinical decision-making.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"154-162"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/13/90/roj-2023-00262.PMC10556844.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41161287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the past, present, and future of postoperative radiotherapy for N2 stage non-small cell lung cancer. 探讨癌症N2期非小细胞肺癌术后放疗的过去、现在和未来。
Pub Date : 2023-09-01 Epub Date: 2023-08-23 DOI: 10.3857/roj.2023.00430
Byoung Hyuck Kim, Jae Sik Kim, Hak Jae Kim

Despite conventionally applied postoperative radiotherapy (PORT) in pathological N2 (pN2) stage non-small cell lung cancer (NSCLC) considering high locoregional recurrence, its survival benefit has been a continuous topic of debate. Although several randomized clinical trials have been conducted, many of them have been withdrawn or analyzed without statistical significance due to slow accrual, making it difficult to determine the efficacy of PORT. Recently, the results of large-scale randomized clinical trials have been published, which showed some improvement in disease-free survival with PORT, but finally had no impact on overall survival. Based on these results, it was expected that the debate over PORT in pN2 patients with NSCLC would come to an end. However, since pN2 patients have different clinicopathologic features, it has become more important to carefully select the patient population who will benefit from PORT. In addition, given the development of systemic treatments such as molecular-targeted therapy and immunotherapy, it is crucial to evaluate whether there is any benefit to PORT in the midst of these recent changes. Therefore, determining the optimal treatment approach for NSCLC pN2 patients remains a complex issue that requires further research and evaluation.

尽管考虑到局部复发率高,病理N2(pN2)期癌症(NSCLC)常规应用术后放疗(PORT),但其生存益处一直是争论的话题。尽管已经进行了几项随机临床试验,但由于累积缓慢,其中许多试验被撤回或分析,没有统计学意义,这使得很难确定PORT的疗效。最近,大规模随机临床试验的结果已经发表,表明PORT的无病生存率有所提高,但最终对总体生存率没有影响。基于这些结果,关于pN2非小细胞肺癌患者PORT的争论有望结束。然而,由于pN2患者具有不同的临床病理特征,因此仔细选择将受益于PORT的患者群体变得更加重要。此外,鉴于分子靶向治疗和免疫疗法等系统治疗的发展,在这些最近的变化中评估PORT是否有任何益处至关重要。因此,确定NSCLC pN2患者的最佳治疗方法仍然是一个需要进一步研究和评估的复杂问题。
{"title":"Exploring the past, present, and future of postoperative radiotherapy for N2 stage non-small cell lung cancer.","authors":"Byoung Hyuck Kim,&nbsp;Jae Sik Kim,&nbsp;Hak Jae Kim","doi":"10.3857/roj.2023.00430","DOIUrl":"10.3857/roj.2023.00430","url":null,"abstract":"<p><p>Despite conventionally applied postoperative radiotherapy (PORT) in pathological N2 (pN2) stage non-small cell lung cancer (NSCLC) considering high locoregional recurrence, its survival benefit has been a continuous topic of debate. Although several randomized clinical trials have been conducted, many of them have been withdrawn or analyzed without statistical significance due to slow accrual, making it difficult to determine the efficacy of PORT. Recently, the results of large-scale randomized clinical trials have been published, which showed some improvement in disease-free survival with PORT, but finally had no impact on overall survival. Based on these results, it was expected that the debate over PORT in pN2 patients with NSCLC would come to an end. However, since pN2 patients have different clinicopathologic features, it has become more important to carefully select the patient population who will benefit from PORT. In addition, given the development of systemic treatments such as molecular-targeted therapy and immunotherapy, it is crucial to evaluate whether there is any benefit to PORT in the midst of these recent changes. Therefore, determining the optimal treatment approach for NSCLC pN2 patients remains a complex issue that requires further research and evaluation.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"144-153"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f1/01/roj-2023-00430.PMC10556840.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41143834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of surface-guided radiation therapy in prostate cancer: comparative analysis of differences with skin marking-guided patient setup. 表面引导放射治疗在前列腺癌症中的应用:与皮肤标记引导的患者设置差异的比较分析。
Pub Date : 2023-09-01 Epub Date: 2023-09-18 DOI: 10.3857/roj.2023.00521
Jaeha Lee, Yeon Joo Kim, Youngmoon Goh, Eunyeong Yang, Ha Un Kim, Si Yeol Song, Young Seok Kim

Purpose: Surface-guided radiation therapy is an image-guided method using optical surface imaging that has recently been adopted for patient setup and motion monitoring during treatment. We aimed to determine whether the surface guide setup is accurate and efficient compared to the skin-marking guide in prostate cancer treatment.

Materials and methods: The skin-marking setup was performed, and vertical, longitudinal, and lateral couch values (labeled as "M") were recorded. Subsequently, the surface-guided setup was conducted, and couch values (labeled as "S") were recorded. After performing cone-beam computed tomography (CBCT), the final couch values was recorded (labeled as "C"), and the shift value was calculated (labeled as "Gap (M-S)," "Gap (M-C)," "Gap (S-C)") and then compared. Additionally, the setup times for the skin marking and surface guides were also compared.

Results: One hundred and twenty-five patients were analyzed, totaling 2,735 treatment fractions. Gap (M-S) showed minimal differences in the vertical, longitudinal, and lateral averages (-0.03 cm, 0.07 cm, and 0.06 cm, respectively). Gap (M-C) and Gap (S-C) exhibited a mean difference of 0.04 cm (p = 0.03) in the vertical direction, a mean difference of 0.35 cm (p = 0.52) in the longitudinal direction, and a mean difference of 0.11 cm (p = 0.91) in the lateral direction. There was no correlation between shift values and patient characteristics. The average setup time of the skin-marking guide was 6.72 minutes, and 7.53 minutes for the surface guide.

Conclusion: There was no statistically significant difference between the surface and skin-marking guides regarding final CBCT shift values and no correlation between translational shift values and patient characteristics. We also observed minimal difference in setup time between the two methods. Therefore, the surface guide can be considered an accurate and time-efficient alternative to skin-marking guides.

目的:表面引导放射治疗是一种使用光学表面成像的图像引导方法,最近被用于患者设置和治疗过程中的运动监测。我们的目的是确定在前列腺癌症治疗中,与皮肤标记引导相比,表面引导设置是否准确有效。材料和方法:进行皮肤标记设置,并记录垂直、纵向和横向沙发值(标记为“M”)。随后,进行表面引导设置,并记录沙发值(标记为“S”)。在进行锥束计算机断层扫描(CBCT)后,记录最终的卧榻值(标记为“C”),并计算偏移值(标记“间隙(M-S)”、“间隙(M-C)”和“间隙(S-C)”),然后进行比较。此外,还比较了皮肤标记和表面引导的设置时间。结果:对125例患者进行了分析,共2735个治疗组分。间隙(M-S)在垂直、纵向和横向平均值上的差异最小(分别为-0.03厘米、0.07厘米和0.06厘米)。Gap(M-C)和Gap(S-C)在垂直方向上表现出0.04厘米(p=0.03)的平均差异,在纵向方向上表现为0.35厘米(p=0.52),在横向方向上表现出来0.11厘米(p=0.91)的平均差。偏移值与患者特征之间没有相关性。皮肤标记引导器的平均设置时间为6.72分钟,表面引导器的设置时间为7.53分钟。结论:在最终CBCT偏移值方面,表面和皮肤标记指南之间没有统计学上的显著差异,平移偏移值与患者特征之间也没有相关性。我们还观察到两种方法在设置时间上的差异最小。因此,表面引导器可以被认为是皮肤标记引导器的准确且省时的替代方案。
{"title":"Application of surface-guided radiation therapy in prostate cancer: comparative analysis of differences with skin marking-guided patient setup.","authors":"Jaeha Lee,&nbsp;Yeon Joo Kim,&nbsp;Youngmoon Goh,&nbsp;Eunyeong Yang,&nbsp;Ha Un Kim,&nbsp;Si Yeol Song,&nbsp;Young Seok Kim","doi":"10.3857/roj.2023.00521","DOIUrl":"10.3857/roj.2023.00521","url":null,"abstract":"<p><strong>Purpose: </strong>Surface-guided radiation therapy is an image-guided method using optical surface imaging that has recently been adopted for patient setup and motion monitoring during treatment. We aimed to determine whether the surface guide setup is accurate and efficient compared to the skin-marking guide in prostate cancer treatment.</p><p><strong>Materials and methods: </strong>The skin-marking setup was performed, and vertical, longitudinal, and lateral couch values (labeled as \"M\") were recorded. Subsequently, the surface-guided setup was conducted, and couch values (labeled as \"S\") were recorded. After performing cone-beam computed tomography (CBCT), the final couch values was recorded (labeled as \"C\"), and the shift value was calculated (labeled as \"Gap (M-S),\" \"Gap (M-C),\" \"Gap (S-C)\") and then compared. Additionally, the setup times for the skin marking and surface guides were also compared.</p><p><strong>Results: </strong>One hundred and twenty-five patients were analyzed, totaling 2,735 treatment fractions. Gap (M-S) showed minimal differences in the vertical, longitudinal, and lateral averages (-0.03 cm, 0.07 cm, and 0.06 cm, respectively). Gap (M-C) and Gap (S-C) exhibited a mean difference of 0.04 cm (p = 0.03) in the vertical direction, a mean difference of 0.35 cm (p = 0.52) in the longitudinal direction, and a mean difference of 0.11 cm (p = 0.91) in the lateral direction. There was no correlation between shift values and patient characteristics. The average setup time of the skin-marking guide was 6.72 minutes, and 7.53 minutes for the surface guide.</p><p><strong>Conclusion: </strong>There was no statistically significant difference between the surface and skin-marking guides regarding final CBCT shift values and no correlation between translational shift values and patient characteristics. We also observed minimal difference in setup time between the two methods. Therefore, the surface guide can be considered an accurate and time-efficient alternative to skin-marking guides.</p>","PeriodicalId":94184,"journal":{"name":"Radiation oncology journal","volume":"41 3","pages":"172-177"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/71/roj-2023-00521.PMC10556842.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41168278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Radiation oncology journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1